Abstract:Only one third of patients suffering from depression will achieve a satisfactory response with first line treatments and more than half of patients will fail to obtain at least 50 % reduction in their symptoms after 3 months of treatment. This article presents a review of the scientific arguments supporting the various therapeutic strategies when confronted to a first treatment failure after an adequate drug trial. Several pharmacological approaches are possible. A first and classical approach is adjusting the drug dosage (optimization). This strategy is coherent with the pharmacological profile of some antidepressant drugs (tricyclic antidepressants, tetracyclic antidepressants, venlafaxine). There is no scientific basis to a dose-effect relationship with the selective serotonin reuptake inhibitors (SSRIs), as minimal doses of these drugs correspond to a high ratio of serotonin transporter occupation; however increasing doses of SSRIs constitutes a usual practice, endorsed by several experts. A second classic strategy is changing an inefficient antidepressant drug to another antidepressant drug (switch). Theoretically, a different pharmacological class should have more chances to be successful; however, in the case of a failure with an SSRI, an inter-class switch has not consistently proven to be superior to an intra-class switch. In some cases, association of antidepressant drugs can also be an advantageous strategy (combination), particularly in the case of partial response with the first prescribed drug. Due to its particular mechanism of action, mirtazapine is often a drug of choice in the case of such an association. Finally, another approach to recommend in case of partial response is associating an antidepressant drug to another class of drugs, such as lithium, atypical antipsychotics or thyroid hormones (potentiation). Lithium has unfailingly proven its efficacy in case of resistance, but the utilization of atypical antipsychotics, at low-doses, has become increasingly common, certainly, because they are easier to handle. Aside from the pharmacological options, we can consider a number of other strategies, first among them is psychotherapy. Most studies assessing the efficacy of psychotherapy were conducted with this therapy as a first-line treatment. More studies of psychotherapy in depression after unsatisfactory response are distinctly needed. Available data seem to indicate that psychotherapy constitutes an efficient alternative, regardless of the type of psychotherapy (results are more robust in cognitive and behavioural therapies and brief interpersonal psychotherapy, in relation with the greater number of studies using these therapies), with effect sizes comparable to the ones obtained with pharmacological options. Among other strategies, physical exercise has been getting more attention lately, even though evidence in this indication remains deceiving for the moment. Lastly, neuromodulation techniques have an unquestionable place. The rTMS has been largely tested with interesting results. Given the time and staff necessary to conduct this therapy, the question has now switched to how precisely select the patients who will most benefit from rTMs, and how long and at what pace should the sessions take place. ECT is undoubtedly the most efficient treatment, but, apart from life-threatening melancholia and other restricted exceptions, it is usually indicated in multi-resistant depression. Some authors suggest using this therapy earlier, as chronicity of the disease is itself a factor of poor response. Finally, this article reviews also the most recent French and International guidelines in managing patients having showed an unsatisfactory response to a first-line treatment.

Psychotherapy in recurrent depression: efficacy, pitfalls, and recommendations

Five-year follow-up of first-episode depression treated with psychodynamic psychotherapy or antidepressants

Enduring effects of psychotherapy, antidepressants and their combination for depression: a systematic review and meta-analysis

Sequential treatment of mood and anxiety disorders

Duration of relapse prevention after cognitive therapy in residual depression: follow-up of controlled trial

Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment

Adjuvant Psychotherapies to Prevent Relapse in Bipolar Disorder: A Randomized Clinical Trial

The Efficacy of Therapies for Post-Stroke Depression in Aging: an Umbrella Review.

Mindfulness-based cognitive therapy to prevent relapse in recurrent depression.

Psychosocial functioning and its influencing factors in patients with depression post-remission: Implications for assessment and interventions

The Efficacy of Cognitive-Behavioral Education and Self-Management on the Recurrent or Deterioration of Depression

Efficacy and suitability of adding short-term psychodynamic psychotherapy (STPP) to pharmacotherapy in patients with depressive disorders: a systematic review

Major depressive disorder: Validated treatments and future challenges

Staying well after depression: trial design and protocol

Optimal duration of combined psychotherapy and pharmacotherapy for patients with moderate and severe depression: A meta-analysis

The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder

Group psychoeducation for patients with bipolar disorder: a retrospective study on effectiveness in delaying relapse episodes and intensity

[How to treat and manage unsatisfactory response?]

The role of primary care in depression relapse: a qualitative study

Relapse of depression in primary care. Rate and clinical predictors

The impact of depression on the treatment of obsessive-compulsive disorder: results from a 5-year follow-up